EF Hutton Initiates Coverage On Pyxis Oncology with Buy Rating, Announces Price Target of $15
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Tony Butler has initiated coverage on Pyxis Oncology (NASDAQ:PYXS) with a Buy rating and a price target of $15.
July 31, 2023 | 11:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pyxis Oncology has received a Buy rating from EF Hutton, with a price target of $15.
The Buy rating and price target set by EF Hutton indicate a positive outlook for Pyxis Oncology. This could potentially attract investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100